Skip to main content

Table 4 Demographics and practice patterns of patients managed for osteoporosis/osteopenia (n = 100)

From: Endocrinology practice patterns of hypothyroidism and osteoporosis management in a U.S. tertiary academic medical center

Age (years)
 Mean ± SD 69.0 ± 11.5
Gender (n)
 Female 87
Race (n)
 Caucasian 74
 Asian 6
 Black 1
 Other 16
 Patient refused to answer 3
Visit type (n)
 New patient visit 38
 Established patient visit 62
Interval between current and next visits, months (mean ± SD) 4.43 ± 2.85
Patients with follow up within 6 months of current visit (n) 44
Indications for initial treatment (n)
 T-score less than −2.5 49
 Fragility fracture 17
 Osteopenia with positive FRAX® risk 6
Patients managed on different prior therapies (n) 54
 One prior therapy 29
 Two prior therapies 18
 Three prior therapies 7
Total duration of any prior therapiesa (months)
 Mean ± SD 73.4 ± 81.9
 Median (range) 48 (0.25–458)
Bone turnover marker(s) checked within 7 months of current visit (n) 68
  1. DXA Dual-energy X-ray absorptiometry
  2. FRAX® Fracture Risk Assessment Tool
  3. aTotal duration of therapy with any of the following, alendronate, zoledronic acid, denosumab, teriparatide, ibandronate, risedronate, and raloxifene (n=37; unknown in n=17)